Impact of mineralocorticoid receptor polymorphisms on urinary electrolyte excretion with and without diuretic drugs
AIM: Polymorphisms in the mineralocorticoid receptor may affect urinary sodium and potassium excretion. We investigated polymorphisms in the MR gene in relation to urinary electrolyte excretion in two separate studies.
PATIENTS & METHODS: The genotype-phenotype association was studied in healthy volunteers after single doses of bumetanide, furosemide, torsemide, hydrochlorothiazide, triamterene and after NaCl restriction.
RESULTS: High potassium excretion under all conditions except torsemide, and high NaCl excretion after bumetanide and furosemide were associated with the A allele of the intron-3 polymorphism (rs3857080). This polymorphism explained 5-10% of the functional variation and in vitro, rs3857080 affected DNA binding of the transcription factor LHX4.
CONCLUSION: rs3857080 may be a promising new candidate for research in cardiac and renal disorders and on antialdosteronergic drugs like spironolactone.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 16(2015), 2 vom: 06. Jan., Seite 115-27 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dalila, Nawar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.01.2016 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs.14.163 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM24560538X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM24560538X | ||
| 003 | DE-627 | ||
| 005 | 20231224141234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs.14.163 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0818.xml |
| 035 | |a (DE-627)NLM24560538X | ||
| 035 | |a (NLM)25616098 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dalila, Nawar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of mineralocorticoid receptor polymorphisms on urinary electrolyte excretion with and without diuretic drugs |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2016 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: Polymorphisms in the mineralocorticoid receptor may affect urinary sodium and potassium excretion. We investigated polymorphisms in the MR gene in relation to urinary electrolyte excretion in two separate studies | ||
| 520 | |a PATIENTS & METHODS: The genotype-phenotype association was studied in healthy volunteers after single doses of bumetanide, furosemide, torsemide, hydrochlorothiazide, triamterene and after NaCl restriction | ||
| 520 | |a RESULTS: High potassium excretion under all conditions except torsemide, and high NaCl excretion after bumetanide and furosemide were associated with the A allele of the intron-3 polymorphism (rs3857080). This polymorphism explained 5-10% of the functional variation and in vitro, rs3857080 affected DNA binding of the transcription factor LHX4 | ||
| 520 | |a CONCLUSION: rs3857080 may be a promising new candidate for research in cardiac and renal disorders and on antialdosteronergic drugs like spironolactone | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a LHX4 | |
| 650 | 4 | |a NR3C2 | |
| 650 | 4 | |a aldosterone | |
| 650 | 4 | |a antihypertensive agents | |
| 650 | 4 | |a hydrochlorothiazide | |
| 650 | 4 | |a loop diuretics | |
| 650 | 4 | |a mineralocorticoid receptor | |
| 650 | 4 | |a pharmacogenetics | |
| 650 | 4 | |a polymorphisms | |
| 650 | 4 | |a triamterene | |
| 650 | 7 | |a Diuretics |2 NLM | |
| 650 | 7 | |a Electrolytes |2 NLM | |
| 650 | 7 | |a Receptors, Mineralocorticoid |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a Hydrochlorothiazide |2 NLM | |
| 650 | 7 | |a 0J48LPH2TH |2 NLM | |
| 650 | 7 | |a Bumetanide |2 NLM | |
| 650 | 7 | |a 0Y2S3XUQ5H |2 NLM | |
| 650 | 7 | |a Sodium Chloride |2 NLM | |
| 650 | 7 | |a 451W47IQ8X |2 NLM | |
| 650 | 7 | |a Furosemide |2 NLM | |
| 650 | 7 | |a 7LXU5N7ZO5 |2 NLM | |
| 650 | 7 | |a Potassium |2 NLM | |
| 650 | 7 | |a RWP5GA015D |2 NLM | |
| 650 | 7 | |a Torsemide |2 NLM | |
| 650 | 7 | |a W31X2H97FB |2 NLM | |
| 650 | 7 | |a Triamterene |2 NLM | |
| 650 | 7 | |a WS821Z52LQ |2 NLM | |
| 700 | 1 | |a Brockmöller, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Tzvetkov, Mladen Vassilev |e verfasserin |4 aut | |
| 700 | 1 | |a Schirmer, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Haubrock, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Vormfelde, Stefan Viktor |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 16(2015), 2 vom: 06. Jan., Seite 115-27 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2015 |g number:2 |g day:06 |g month:01 |g pages:115-27 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs.14.163 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2015 |e 2 |b 06 |c 01 |h 115-27 | ||